Correlation between nuclear grade and biological prognostic variables in invasive breast cancer

Breast Cancer

Volumn 8, Issue 2, 2001, Pages 105-110

  Yang, Qifeng ^a,b   Mori, Ichiro ^b   Sakurai, Takeo ^a   Yoshimura, Goro ^a   Suzuma, Takaomi ^a   Nakamura, Yasushi ^b   Nakamura, Misa ^b   Taniguchi, Emiko ^b   Tamaki, Takeshi ^a   Umemura, Teiji ^a   Kakudo, Kennichi ^b  

^a Department of Surgery   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Bcl 2; Breast cancer; C erbB 2; Lymph node metastasis; MIB 1; Nuclear grade

Indexed keywords

TUMOR MARKER;

ARTICLE; BREAST TUMOR; CANCER INVASION; CELL NUCLEUS; CHEMISTRY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL NUCLEUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035222501     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967488     Document Type: Article

References (21)

1. World Health Organization Histological Typing of Breast Tumors 2nd edn, WHO, Geneva, 1981.
2. Tsuda H, Akiyama F, Kurosumi M, et al: Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section. The efficacy and limitations of repeated slide conferences for improving interobserver agreement when judging nuclear atypia of breast cancer. Jpn J Clin Oncol 29:68-73, 1999.
3. Tsuda H, Akiyama F, Kurosumi M, et al: Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section. Monitoring of interobserver agreement in nuclear atypia scoring of nodenegative breast carcinomas judged at individual collaborating hospitals in the National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) protocol. Jpn J Clin Oncol 29:413-420, 1999.
4. Watanabe T: Protocol for clinical trials (1). Phase EI randomized comparison of postoperative adjuvant chemotherapy with 2-year oral UFT (uracil/tegafur) versus six-cycle CMF (cyclophosphamide/methotrexate/5- fluorouracil) in high-risk node-negative breast cancer patients. Jpn J Clin Oncol 28:77-80, 1998. (Pubitemid 128527487)
5. Tsuda H, Akiyama F, Kurosumi M, et al: Establishment of histological criteria for high-risk node-negative breast carcinoma for the Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) protocol. Jpn J Clin Oncol 28:486-491, 1998. (Pubitemid 128527326)
6. Yang Q, Sakurai T, Yoshimura G, et al: Expression of Bcl-2 but not Bax or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma. Breast Cancer Res Treat 61:211-216, 2000. (Pubitemid 30609554)
7. Yang Q, Shan L, Goro Yoshimura, et al: Thymidine Phosphorylase Expression in Invasive breast Carcinoma: Correlations with in vitro Chemosensitiviry to 5-fluorouracil. Anticancer Res 19:5543-5546, 1999. (Pubitemid 30093323)
8. Ellis PSJ, Whitehead R: Mitosis counting-a need for reappraisal. Hum Pathol 12:3-4, 1981.
9. Mann R, Elston CW, Hunter S, et al: Evaluation of mitotic activity as a component of histological grade and its contribution to prognosis in primary breast carcinoma. J Pathol 146:271, 1985.
10. Tsujimoto Y, Bashir MM, Givol I, et al: DNA rearrangements in human follicular lymphoma can involve the 5' or the 3' region of the bcl-2 gene. Pro Natl Acad Set USA 84:1329-31, 1987. (Pubitemid 17027346)
11. Joensuu H, Pylkkanen L, Toikkanen S: Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 145:1191-1198, 1994. (Pubitemid 24345666)
12. van Slooten H, Clahsen PC, van Dierendonck JH, et al: Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br J Cancer 74:74-85, 1996.
13. Home GM, Anderson JJ, Tiniakos DG, et al: p53 protein as a prognostic indicator in breast carcinoma: A comparision of four antibodies for immunohistochemistry. Br J Cancer 73:29-36, 1996.
14. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989. (Pubitemid 19147683)
15. Berger MS, Locher GW, Saurer S, et al: Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48:1238-1243, 1988. (Pubitemid 18075540)
16. Cardiff RD: Cellular and molecular aspects of neoplastic progression in the mammary gland. Eur J Cancer Clin Oncol 24:15-20, 1988. (Pubitemid 18009330)
17. Van de Vijver MJ, Peterse JL, Modi W: Neu-protein overexpression in breast cancer: association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239-1245, 1988. (Pubitemid 18267063)
18. Berns EMJJ, Foekens JA, van Staveren IL, et al: Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment. Gene 159:11-19, 1995.
19. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10:1049-1056, 1992.
20. Gullick WJ, Love SB, Wright C, et al: c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 163:434-438, 1991.
21. Andrulis IL, Bull SB, Blackstein ME, et al: neu/erbB2 amplification identifies a poor-prognosis group of women with node negative breast cancer. J Clin Oncol 16:1340-1349, 1998. (Pubitemid 28175749)